What do systematic reviews say?

Summary of findings table ‐ Oral classical immunosuppressants (prednisolone or cyclosporine) vs placebo

• Treatments for alopecia areata: a network meta‐analysis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 79 participants
  Very low

Summary of findings table ‐ Oral small molecule inhibitors (apremilast or baricitinib) vs placebo

Summary of findings table ‐ Oral small molecule inhibitors… leads to higher long‐term hair regrowth ≥ 75% (greater than 26 weeks of compared with placebo (high certainty).

• Treatments for alopecia areata: a network meta‐analysis 2023 · Cochrane Headline outcomes only
  RR 8.49 [4.7, 15.34]
  2 studies · 1200 participants
  High

Summary of findings table ‐ Oral small molecule inhibitors (ruxolitinib) vs oral small molecule inhibitors (tofacitinib)

It is very uncertain whether summary of findings table ‐ Oral small molecule inhibitors… changes short‐term hair regrowth ≥ 75% (between 12 and 26 weeks of compared with oral small molecule inhibitors (tofacitinib) (very low certainty).

• Treatments for alopecia areata: a network meta‐analysis 2023 · Cochrane Headline outcomes only
  RR 1.08 [0.77, 1.52]
  1 study · 80 participants
  Very low

Summary of findings table ‐ Oral small molecule inhibitors (ruxolitinib) vs oral small molecule inhibitors (tofacitinib)

• Treatments for alopecia areata: a network meta‐analysis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 80 participants
  Very low

Summary of findings table ‐ Oral small molecule inhibitors (ruxolitinib) vs oral small molecule inhibitors (tofacitinib)

The review found no eligible studies for this question.

• Treatments for alopecia areata: a network meta‐analysis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings table ‐ Oral small molecule inhibitors (ruxolitinib) vs oral small molecule inhibitors (tofacitinib)

The review found no eligible studies for this question.

• Treatments for alopecia areata: a network meta‐analysis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings table ‐ Topical small molecule inhibitors (ruxolitinib) vs placebo

Summary of findings table ‐ Topical small molecule inhibitors… showed no clear difference in short‐term hair regrowth ≥ 75% (between 12 and 26 weeks of compared with placebo (low certainty).

• Treatments for alopecia areata: a network meta‐analysis 2023 · Cochrane Headline outcomes only
  RR 5 [0.25, 100.89]
  1 study · 78 participants
  Low

Summary of findings table ‐ Topical small molecule inhibitors (ruxolitinib) vs placebo

It is very uncertain whether summary of findings table ‐ Topical small molecule inhibitors… changes incidence of serious adverse events compared with placebo (very low certainty).

• Treatments for alopecia areata: a network meta‐analysis 2023 · Cochrane Headline outcomes only
  RR 0.33 [0.01, 7.94]
  1 study · 78 participants
  Very low

Summary of findings table ‐ Topical small molecule inhibitors (ruxolitinib) vs placebo

The review found no eligible studies for this question.

• Treatments for alopecia areata: a network meta‐analysis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings table ‐ Topical small molecule inhibitors (ruxolitinib) vs placebo

The review found no eligible studies for this question.

• Treatments for alopecia areata: a network meta‐analysis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings table ‐ Contact immunotherapy (diphencyprone or squaric acid dibutil ester) vs placebo

It is very uncertain whether summary of findings table ‐ Contact immunotherapy (diphencyprone or… changes short‐term hair regrowth ≥ 75% (between 12 and 26 weeks of compared with placebo (very low certainty).

• Treatments for alopecia areata: a network meta‐analysis 2023 · Cochrane Headline outcomes only
  RR 1.16 [0.79, 1.71]
  1 study · 99 participants
  Very low

Summary of findings table ‐ Oral classical immunosuppressants (prednisolone or cyclosporine) vs placebo

• Treatments for alopecia areata: a network meta‐analysis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 36 participants
  Very low

Summary of findings table ‐ Contact immunotherapy (diphencyprone or squaric acid dibutil ester) vs placebo

The review found no eligible studies for this question.

• Treatments for alopecia areata: a network meta‐analysis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings table ‐ Contact immunotherapy (diphencyprone or squaric acid dibutil ester) vs placebo

The review found no eligible studies for this question.

• Treatments for alopecia areata: a network meta‐analysis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings table ‐ Contact immunotherapy (diphencyprone or squaric acid dibutil ester) vs placebo

The review found no eligible studies for this question.

• Treatments for alopecia areata: a network meta‐analysis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings table ‐ Contact immunotherapy (diphencyprone or squaric acid dibutil ester) vs hair growth stimulants (minoxidil)

It is very uncertain whether summary of findings table ‐ Contact immunotherapy (diphencyprone or… changes short‐term hair regrowth ≥ 75% (between 12 and 26 weeks of compared with hair growth stimulants (minoxidil) (very low certainty).

• Treatments for alopecia areata: a network meta‐analysis 2023 · Cochrane Headline outcomes only
  RR 1.16 [0.79, 1.71]
  1 study · 99 participants
  Very low

Summary of findings table ‐ Contact immunotherapy (diphencyprone or squaric acid dibutil ester) vs hair growth stimulants (minoxidil)

The review found no eligible studies for this question.

• Treatments for alopecia areata: a network meta‐analysis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings table ‐ Contact immunotherapy (diphencyprone or squaric acid dibutil ester) vs hair growth stimulants (minoxidil)

The review found no eligible studies for this question.

• Treatments for alopecia areata: a network meta‐analysis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings table ‐ Contact immunotherapy (diphencyprone or squaric acid dibutil ester) vs hair growth stimulants (minoxidil)

The review found no eligible studies for this question.

• Treatments for alopecia areata: a network meta‐analysis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings table ‐ Contact immunotherapy (diphencyprone) + hair growth stimulants (minoxidil) vs contact immunotherapy (diphencyprone)

It is very uncertain whether summary of findings table ‐ Contact immunotherapy (diphencyprone) +… changes short‐term hair regrowth ≥ 75% (between 12 and 26 weeks of compared with contact immunotherapy (diphencyprone) (very low certainty).

• Treatments for alopecia areata: a network meta‐analysis 2023 · Cochrane Headline outcomes only
  RR 0.67 [0.13, 3.44]
  1 study · 30 participants
  Very low